Several studies have shown an inverse correlation between EGFR expression and disease-free and overall survival of breast cancer.7, 8, 9, 10 It is well established that EGFR activates two critical signaling pathways, the MAPK/ERK1/2 and PI3K/AKT pathways, leading to increased cancer cell proliferation and metastasis.1, 2, 3 In this study, we identify a novel HIF1α/miR-338-3p/EYA2 axis that controls EGFR-mediated tumor growth and metastasis (Supplementary Figure S8). The gene discussed is MAPK3; the disease is breast carcinoma.